Purpose Sutureless aortic valve replacement (AVR) with Perceval has offered advantages to the standard valve. Herein we present the 30-day clinical outcomes in patients underwent AVR with Perceval from an Australia experience. Methodology From September 2014 to June 2023, 297 patients underwent sutureless aortic valve replacement with Perceval (Corcym) in two hospitals in Townsville, Australia. AVR with concomitant procedures were performed in 117 patients. Peri-procedural and 30-day post-operative follow-up outcome are studied as a cross-sectional retrospective study. Results The mean age of patients was 72.9 years with 64.1% female. AVR performed via mini-sternotomy in 27 (9%) patients and 204 (69.6%) patients received large and extra-large valves (39.2% large and 30.4% extra-large). The median cross-clamp time (CCT) and cardiopulmonary bypass (CPB) time in isolated AVR were 54.8 min and 72.4 min, respectively, and in patients with AVR and concomitant procedures, CCT was 69.9 min with 94.7 min CPB time. Post valve implantation intra-operative Transesophageal Echocardiogram (TOE) did not show any paravalvular leak (PVL) in 291 (98%) patients and the remaining 6 (2%) patients had trivial paravalvular leak. There was no PVL on the TOE in 30-day follow-up in all patients. Post-operatively, the mean intensive care unit and hospital stay were 2.3 and 6.8 days, respectively. Permanent pacemaker (PPM) insertion was required in 19 (6%) subjects and cardiac mortality within 30 days was reported in 2 patients (0.6%) with 2 years follow up from a survival analysis plot revealed to be 89.2%. Conclusions Our study demonstrated excellent short-term outcomes using Perceval sutureless aortic valves. The high implantation success rate and low post-op complication rate reveals a promising alternative of Perceval to conventional biological AVR. Perceval can specially be offered in high risk patients whom long pump time would be a precluding factor for surgical AVR.